(NASDAQ: ATXS) Astria Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Astria Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ATXS's revenue for 2026 to be $274,515,305, with the lowest ATXS revenue forecast at $274,515,305, and the highest ATXS revenue forecast at $274,515,305. On average, 2 Wall Street analysts forecast ATXS's revenue for 2027 to be $6,496,953,723, with the lowest ATXS revenue forecast at $818,055,609, and the highest ATXS revenue forecast at $12,175,851,838.
In 2028, ATXS is forecast to generate $11,186,333,970 in revenue, with the lowest revenue forecast at $1,751,407,646 and the highest revenue forecast at $33,841,697,770.